Roche Recalls Viracept
Basel, Switzerland (June 6)-Roche, in an agreement with the European Medicines Agency and the Swiss Agency for Therapeutic Products, recalled all batches of "Viracept" (nelfinavir) powder and tablets in Europe and some other regions of the world.
Basel, Switzerland (June 6)-Roche, in an agreement with the European Medicines Agency (EMEA, London) and the Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland), recalled all batches of “Viracept” (nelfinavir) powder and tablets in Europe and some other regions of the world.
Viracept is a protease inhibitor supplied by Roche outside the United States and Canada. The United States, Canada, and Japan are not affected by the recall.
Roche received several reports that some batches of Viracept 250-mg tablets had a strange odor. A chemical analysis of the affected tablets showed they contained higher than normal levels of methane sulfonic acid ethylester.
Ethyl mesylate is a genotoxic substance, according to EMEA. “The level of risk to patients resulting from this contamination is difficult to measure, and is currently under further evaluation,” said EMEA in a press release.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
